- •The risk of venous thromboembolism in acute stroke persists beyond hospitalization.
- •The role of extended venous thromboprophylaxis in acute stroke remain controversial.
- •Extended thromboprophylaxis seemed reduce the risk of venous thrombosis in acute stroke
- •Major bleeding risk appeared similar between extended and standard thromboprophylaxis.
Materials and methods
Collaborators GBDS. Global, regional, and national burden of stroke, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019; 18: 439-58. 10.1016/S1474-4422(19)30034-1.
- Venous thromboembolism after acute stroke.Stroke. 2001; 32: 1443-1448https://doi.org/10.1161/01.str.32.6.1443-b
- Venous thromboembolism: disease burden, outcomes and risk factors.J. Thromb. Haemost. 2005; 3: 1611-1617https://doi.org/10.1111/j.1538-7836.2005.01415.x
- Ischemic stroke and risk of venous thromboembolism in the general population: the Tromsø study.J. Am. Heart Assoc. 2016; 5https://doi.org/10.1161/JAHA.116.004311
- Venous thromboembolism after acute stroke.Stroke. 2001; 32: 262-267https://doi.org/10.1161/01.str.32.1.262
- The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group.Lancet. 1997; 349: 1569-1581
- What is the optimal pharmacological prophylaxis for the prevention of deep-vein thrombosis and pulmonary embolism in patients with acute ischemic stroke?.Thromb. Res. 2007; 119: 265-274https://doi.org/10.1016/j.thromres.2006.03.010
- Extended thromboprophylaxis with betrixaban in acutely ill medical patients.N. Engl. J. Med. 2016; 375: 534-544https://doi.org/10.1056/NEJMoa1601747
- Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial.Ann. Intern. Med. 2010; 153: 8-18https://doi.org/10.7326/0003-4819-153-1-201007060-00004
- Rivaroxaban for thromboprophylaxis in acutely ill medical patients.N. Engl. J. Med. 2013; 368: 1945-1946https://doi.org/10.1056/NEJMc1303641
- Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141 (e195S–e226S)https://doi.org/10.1378/chest.11-2296
- Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.Chest. 2012; 141 (e601S-e36S)https://doi.org/10.1378/chest.11-2302
- Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.PLoS Med. 2009; 6e1000097https://doi.org/10.1371/journal.pmed.1000097
- Assessing risk of bias in included studies.Cochrane Handbook for Systematic Reviews of Interventions Version. 520. 2017
- Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients.J. Thromb. Haemost. 2005; 3: 692-694https://doi.org/10.1111/j.1538-7836.2005.01204.x
Deeks J, Higgins J, Altma nD. Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.
- Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients.N. Engl. J. Med. 2011; 365: 2167-2177https://doi.org/10.1056/NEJMoa1110899
- Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study.Stroke. 2013; 44: 249-251https://doi.org/10.1161/STROKEAHA.112.659797
- Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness.N. Engl. J. Med. 2018; 379: 1118-1127https://doi.org/10.1056/NEJMoa1805090
- Rivaroxaban for thromboprophylaxis in acutely ill medical patients.N. Engl. J. Med. 2013; 368: 513-523https://doi.org/10.1056/NEJMoa1111096
- Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet Neurol. 2019; 18: 459-480https://doi.org/10.1016/S1474-4422(18)30499-X
- Association between low-dose rivaroxaban with or without aspirin and ischemic stroke subtypes: a secondary analysis of the COMPASS trial.JAMA Neurol. 2020; 77: 43-48https://doi.org/10.1001/jamaneurol.2019.2984
- Clinical research collaboration NuETTN, and the POINT Investigators. Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.N. Engl. J. Med. 2018; 379: 215-225https://doi.org/10.1056/NEJMoa1800410
- Comparison of risk factors for the competing risks of coronary heart disease, stroke, and venous thromboembolism.Am. J. Epidemiol. 2005; 162: 975-982https://doi.org/10.1093/aje/kwi309
- Risk of thromboembolism varies, depending on category of immobility in outpatients.Ann. Emerg. Med. 2009; 54: 147-152https://doi.org/10.1016/j.annemergmed.2008.10.033
- of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients.Blood Adv. 2018; 2: 3198-3225https://doi.org/10.1182/bloodadvances.2018022954
- Extended duration of thromboprophylaxis for medically ill patients: a systematic review and meta-analysis of randomised controlled trials.Intern. Med. J. 2020; 50: 192-199https://doi.org/10.1111/imj.14417
- Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association.Stroke. 2019; 50: e344-e418https://doi.org/10.1161/STR.0000000000000211
Food and Drug Administration. Response to the notification of Non-Compliance with PREA, NDA 208383. Accessed at https://www.fda.gov/media/143144/download on 14 September 2021.